Semaglutide

Semaglutide (GLP-1 Receptor Agonist)

Evidence & Status

  • FDA Approved
  • Strong Human Evidence
  • Established

At a Glance

An FDA-approved GLP-1 receptor agonist used in the treatment of type 2 diabetes and chronic weight management. One of the most extensively studied metabolic compounds available, with large-scale clinical trial data supporting its effects on blood sugar, body weight, and cardiovascular health.

Plain English

Researchers study semaglutide because it closely mimics a natural hormone called GLP-1, which plays a key role in signalling fullness after eating and regulating blood sugar levels. Large clinical trials have confirmed its effectiveness in reducing blood glucose in people with type 2 diabetes, and in supporting significant weight reduction in people with obesity. Scientists are also investigating its potential benefits in areas including liver disease, kidney health, and — in early-stage research — neurological conditions. It is one of the few compounds in this database with robust human clinical evidence across multiple indications.

Overview

A long-acting GLP-1 receptor agonist available in FDA-approved products with formulation- and indication-specific labeling. Wegovy injection is labeled for chronic weight management, cardiovascular-risk reduction in eligible adults, and noncirrhotic MASH with moderate-to-advanced fibrosis; Ozempic and Rybelsus have separate diabetes labels.

Research Summary

Large randomized trials support semaglutide for labeled metabolic indications. SUSTAIN-6 demonstrated fewer major adverse cardiovascular events with semaglutide versus placebo in adults with type 2 diabetes at elevated cardiovascular risk (Marso et al. 2016). STEP 1 found substantial mean weight loss with semaglutide 2.4 mg in adults with overweight or obesity, and SELECT demonstrated cardiovascular-event reduction in adults with established cardiovascular disease and overweight or obesity without diabetes. The FLOW trial (completed January 2024) found that semaglutide reduced the composite risk of kidney failure and major kidney-disease events in adults with type 2 diabetes and chronic kidney disease. The EVOKE Phase III trial (primary endpoint completed September 2025) found that semaglutide did not slow clinical progression in early Alzheimer's disease; this completed negative result should not be characterized as an unanswered or ongoing program. The current Wegovy label includes a noncirrhotic MASH indication with moderate-to-advanced fibrosis and a high-dose 7.2 mg weekly option (approved March 2026, STEP UP trial). Wegovy is also available as an oral tablet formulation; both injection and oral tablet forms are covered under the same NDA label.

Research Areas

  • Type 2 diabetes
  • Obesity & weight loss
  • Cardiovascular risk reduction
  • NASH/MASH
  • Kidney protection
  • Alzheimer's disease (Phase III completed; primary endpoint not met)

Safety & Risks

Serious Risks

  • Pancreatitis (rare)
  • Gallbladder disease
  • Medullary thyroid carcinoma risk (boxed warning; contraindicated with MEN2/MTC history)
  • Hypoglycemia (when combined with insulin/sulfonylureas)
  • Gastroparesis

Reported Side Effects

  • Nausea (very common)
  • Vomiting
  • Diarrhea
  • Constipation
  • Abdominal pain
  • Fatigue
  • Decreased appetite
United States
Prescription: FDA-approved semaglutide products have formulation- and indication-specific labels, including Wegovy for chronic weight management, cardiovascular-risk reduction in eligible adults, and noncirrhotic MASH with moderate-to-advanced fibrosis
United Kingdom
Prescription (MHRA-approved)
Australia
Prescription (TGA-approved)
Canada
Prescription (Health Canada approved)

Citations & Sources